Breast cancer, version 4.2021 featured updates to the NCCN guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice LyonsJennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

216 Scopus citations

Abstract

The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.

Original languageEnglish (US)
Pages (from-to)484-494
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number5
DOIs
StatePublished - May 2021

Funding

Ingrid A. Mayer, MD, Panel Member, has disclosed receiving consulting fees from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., GlaxoSmithKline, Immunomedics, Inc., Novartis Pharmaceuticals Corporation, Eli Lilly and Company, MacroGenics, Inc., Puma Biotechnology, and Seattle Genetics, Inc.; honoraria from AstraZeneca Pharmaceuticals LP, Genentech, Inc., and Novartis Pharmaceuticals Corporation; and grant/research support from Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc. This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie.

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Breast cancer, version 4.2021 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this